In today’s NewsFlash Roundup, Boston Scientific’s CEO retires, the MLSC gives out a lot of money, and a glaucoma drug passes a Phase 1/2 trial. 

• Tobin retires from Boston Scientific; Elliot named new CEO

Ray Elliot replaces Tobin as the third CEO in Boston Scientific history. Elliot is a former Boston Scientific board member. In his new position, he will rejoin the board.

• Mass. life science research buoyed by $1.3M grants from MLSC

The Massachusetts Life Sciences Center awarded seven recipients with a second round of grants of up to $100,000 per year for up to two years; each recipient’s research institution will match the funding. In total, the researchers could receive $2.8 million.

• Inotek advances glaucoma drug

Researchers found that the drug target, called INO-8875, reduced intraocular pressure by a statistically significant amount. Intraocular pressure is a risk factor for vision loss associated with glaucoma and is thought to be one of the causes of the disease.

• MLSC continues funding Mass. stem cell bank

The International Stem Cell Registry at the University of Massachusetts Medical School will receive $695,000 from the Massachusetts Life Sciences Center (MLSC) after the center’s board of directors approved to continue funding the registry.